Verrica Pharmaceuticals Inc
VRCA
查看详细走势图
7.820USD
-0.290-3.58%
收盘 12/19, 16:00（美东）报价延迟15分钟
74.21M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.58%
5天
-1.26%
1月
+85.75%
6月
+33.72%
今年开始到现在
+11.71%
1年
+12.65%
查看详细走势图
TradingKey Verrica Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Verrica Pharmaceuticals Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名83/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.33。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Verrica Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
16.333
目标均价
+101.40%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Verrica Pharmaceuticals Inc亮点
亮点风险
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
业绩增长期
公司处于发展阶段，最新年度总收入7.57M美元
利润高增长
公司净利润处于行业前列，最新年度总收入7.57M美元
估值低估
公司最新PE估值-2.74，处于3年历史低位
机构减仓
最新机构持股2.46M股，环比减少37.23%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值225.21K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.95
Verrica Pharmaceuticals Inc新闻
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Verrica Pharmaceuticals Inc简介
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
公司代码VRCA
公司Verrica Pharmaceuticals Inc
CEORieger (Jayson)
网址https://verrica.com/
常见问题
Verrica Pharmaceuticals Inc(VRCA)的当前股价是多少？
Verrica Pharmaceuticals Inc(VRCA)的当前股价是 7.820。
Verrica Pharmaceuticals Inc的股票代码是什么？
Verrica Pharmaceuticals Inc的股票代码是VRCA。
Verrica Pharmaceuticals Inc股票的52周最高点是多少？
Verrica Pharmaceuticals Inc股票的52周最高点是9.821。
Verrica Pharmaceuticals Inc股票的52周最低点是多少？
Verrica Pharmaceuticals Inc股票的52周最低点是3.280。
Verrica Pharmaceuticals Inc的市值是多少？
Verrica Pharmaceuticals Inc的市值是74.21M。
Verrica Pharmaceuticals Inc的净利润是多少？
Verrica Pharmaceuticals Inc的净利润为-76.58M。
现在Verrica Pharmaceuticals Inc(VRCA)的股票是买入、持有还是卖出？
根据分析师评级，Verrica Pharmaceuticals Inc(VRCA)的总体评级为买入，目标价格为16.333。
Verrica Pharmaceuticals Inc(VRCA)股票的每股收益（EPS TTM）是多少
Verrica Pharmaceuticals Inc(VRCA)股票的每股收益（EPS TTM）是-2.858。
相关品种
